Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.
Cancer Immunol Immunother
; 69(5): 683-687, 2020 May.
Article
en En
| MEDLINE
| ID: mdl-32152702
ABSTRACT
More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to healthy self-tissues in the majority. We have proposed that a major mechanism of irAEs is similar to a graft-versus-malignancy effect of graft-versus-host disease. To verify our hypothesis, we retrieved post-marketing data of adverse events from the U.S. Food and Drug Administration Adverse Event Reporting System. A significant positive correlation was revealed in 7677 patients between the reporting odds ratio of irAEs during immune checkpoint inhibitor therapy and the corresponding tumor mutational burden across 19 cancer types. These results can be interpreted to mean that the ICI drugs unleashed T cells against "altered-self," self, and tumors resulting in better overall survival.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfocitos T
/
Autotolerancia
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Antineoplásicos Inmunológicos
/
Neoplasias
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Cancer Immunol Immunother
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Año:
2020
Tipo del documento:
Article